Editorial
Giant cell arteritis and polymyalgia rheumatica: two different but often overlapping conditions

https://doi.org/10.1016/j.semarthrit.2003.09.007Get rights and content

Abstract

Objectives

Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are common and frequently overlapping diseases. In this manuscript similarities and differences between these conditions have been assessed.

Methods

A retrospective review of the literature was conducted. Reports emphasizing features in common and possible differences are reviewed.

Results

GCA and PMR are characterized by late age at disease onset, are more common in women, exhibit evidence of a systemic inflammatory response, and generally respond well to corticosteroids. In biopsy-proven GCA, PMR manifestations are observed in up to 50% of cases. PMR may be the presenting feature in patients who later develop typical cranial manifestations of GCA. However, PMR manifestations may be observed in diverse conditions other than GCA. Patients with isolated PMR are younger than those with PMR associated to biopsy-proven GCA and exhibit milder inflammatory disease as shown by significantly less abnormality in most laboratory findings. Recent observations have shown that the frequency of pathologic features of GCA in temporal artery biopsies of patients with clinically isolated PMR is less than that previously reported. Besides different steroid requirements, GCA is associated with more vascular complications. Genetic differences, in particular different HLA-DRB1 associations, also have been observed.

Conclusions

Polymyalgia manifestations may be observed in patients with biopsy-proven GCA, but isolated PMR may be the only clinical feature or the phenotypic expression of a number of conditions. Clinical features and immunogenetic studies show subtle differences between GCA and PMR.

Section snippets

Are GCA and PMR different clinical expressions of a common disease?

Both conditions are characterized by late age at disease onset, are more common in women, exhibit evidence of systemic inflammatory response, and generally respond well to steroids (1). The frequency of GCA and PMR increases with aging and peaks in patients older than 70 years 1, 2.

GCA patients often present clinical manifestations of PMR (3). In biopsy-proven GCA PMR manifestations are observed in up to 50% of cases 1, 2, 8, 9. PMR may be the presenting feature in patients who later develop

Conclusions

Both GCA are common and often concurrent diseases in the elderly. Although in some cases polymyalgia manifestations may be observed in patients with biopsy-proven GCA, PMR may be the only clinical feature or the phenotypic expression of a great variety of conditions. Clinical features and immunogenetic studies show subtle differences between GCA and PMR.

Miguel A. Gonzalez-Gay MD, PhD: Rheumatology Division, Hospital Xeral-Calde, Lugo, Spain.

References (41)

  • M.A Gonzalez-Gay et al.

    Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients

    Medicine (Baltimore)

    (2000)
  • T.Y Chuang et al.

    Polymyalgia rheumaticaA 10-year epidemiologic and clinical study

    Ann Intern Med

    (1982)
  • M.A Gonzalez-Gay et al.

    Giant cell arteritis in Lugo, SpainA more frequent disease with fewer classic features

    J Rheumatol

    (1997)
  • R.I Rynes et al.

    Development of giant cell (temporal) arteritis in a patient “adequately” treated for polymyalgia rheumatica

    Ann Rheum Dis

    (1977)
  • M.A Papadakis et al.

    Temporal arteritis after normalization of erythrocyte sedimentation rate

    Arch Intern Med

    (1986)
  • C.A Smith et al.

    The epidemiology of giant cell arteritis. Report of a ten-year study in Shelby County, Tennessee

    Arthritis Rheum

    (1983)
  • C Salvarani et al.

    Epidemiology of polymyalgia rheumatica in Olmsted County, Minnesota, 1970–1991

    Arthritis Rheum

    (1995)
  • C.M Weyand et al.

    The HLA-DRB1 locus as a genetic component in giant cell arteritis

    J Clin Invest

    (1992)
  • C.M Weyand et al.

    HLA-DRB1 alleles in polymyalgia rheumatica, giant cell arteritis, and rheumatoid arthritis

    Arthritis Rheum

    (1994)
  • M.A Gonzalez-Gay et al.

    Systemic vasculitis in adults in northwestern Spain, 1988–1997. Clinical and epidemiologic aspects

    Medicine (Baltimore)

    (1999)
  • Cited by (152)

    • Polymyalgia rheumatica

      2023, The Lancet
    • Unmet need in the treatment of polymyalgia rheumatica and giant cell arteritis

      2022, Best Practice and Research: Clinical Rheumatology
    View all citing articles on Scopus

    Miguel A. Gonzalez-Gay MD, PhD: Rheumatology Division, Hospital Xeral-Calde, Lugo, Spain.

    View full text